Randomized non-inferiority study comparing a strategy maintaining current enfuvirtide-based antiretroviral therapy to a strategy replacing enfuvirtide by an integrase inhibitor (raltegravir) in HIV-1 infected subjects with plasma HIV-1 RNA levels below 400 copies per ml

Trial Profile

Randomized non-inferiority study comparing a strategy maintaining current enfuvirtide-based antiretroviral therapy to a strategy replacing enfuvirtide by an integrase inhibitor (raltegravir) in HIV-1 infected subjects with plasma HIV-1 RNA levels below 400 copies per ml

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2014

At a glance

  • Drugs Antiretrovirals; Enfuvirtide; Raltegravir
  • Indications HIV-1 infections
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms EASIER
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Jun 2013 Results of a biomarker analysis published in the Journal of Infectious Diseases.
    • 08 Mar 2012 Results reporting the effects of treatment on levels of inflammatory and coagulation biomarkers presented at the 19th Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top